See the DrugPatentWatch profile for Zerbaxa
What is Zerbaxa, and what is it used for?
Zerbaxa (ceftolozane and tazobactam) is an antibiotic combination used to treat certain serious bacterial infections, particularly complicated urinary tract infections and complicated intra-abdominal infections, when the cause is susceptible to the drugs’ activity. It is administered by injection (IV). [1]
How does Zerbaxa work?
Zerbaxa combines:
- Ceftolozane, an antibiotic (a cephalosporin) that targets bacterial cell-wall synthesis.
- Tazobactam, a beta-lactamase inhibitor that helps protect ceftolozane from some bacterial resistance mechanisms that break down beta-lactam antibiotics. [1]
What dosing and administration considerations matter?
Because Zerbaxa is given as an IV antibiotic, dosing is typically adjusted based on factors such as kidney function and the specific indication being treated. (Clinicians determine the exact regimen based on local prescribing information and patient factors.) [1]
What side effects do people commonly ask about?
Common antibiotic-associated risks apply, including gastrointestinal effects (such as diarrhea or nausea) and possible allergic reactions. Serious adverse reactions can occur with any antibiotic, and clinicians screen for allergy history and monitor patients during treatment. [1]
Is Zerbaxa still under patent protection, and who makes it?
Zerbaxa is associated with patent and exclusivity coverage that can affect biosimilar/generic entry timelines and competitive products. For the latest patent/exclusivity details and related filings, DrugPatentWatch.com tracks drug patent status and litigation signals for products like Zerbaxa. [2]
Sources
- https://www.drugs.com/zerbaxa.html
- https://www.drugpatentwatch.com/